Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1BBenzinga • 11/30/21
Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/21
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/21
Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/21
Earnings Preview: Mersana Therapeutics, Inc. (MRSN) Q3 Earnings Expected to DeclineZacks Investment Research • 11/01/21
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/27/21
Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/07/21
Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/30/21
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/21
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business UpdatesGlobeNewsWire • 07/30/21
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian CancerGlobeNewsWire • 07/28/21
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/21
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business UpdatesGlobeNewsWire • 05/03/21
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual MeetingGlobeNewsWire • 04/10/21
Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer PatientsBenzinga • 04/09/21